Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.46 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.39 |
| ▸ | MERTK | Q12866 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.37 |
| ▸ | HTR1E | P28566 | 1/20 | 0.36 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.35 |
| ▸ | GCGR | P47871 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL719331 | 0.86 | GCGR (0.53) | GCGR | |
| SCHEMBL720764 | 0.85 | RCE1 (0.46) | RCE1PDE7AMERTKF10TP53 | |
| SCHEMBL719577 | 0.85 | GCGR (0.37) | RCE1TP53POLBMAPTABCC1 | |
| SCHEMBL718249 | 0.84 | RCE1 (0.44) | RCE1PDE7AMERTKF10TP53 | |
| SCHEMBL719002 | 0.78 | RCE1 (0.52) | RCE1MERTKMAPTPGRKDM4E | |
| SCHEMBL718796 | 0.77 | RCE1 (0.53) | RCE1MERTKHTR1ES1PR3PGR | |
| SCHEMBL3109922 | 0.76 | RCE1 (0.52) | RCE1PDE7APOLBMAPTHTR1E | |
| SCHEMBL3099322 | 0.76 | RCE1 (0.53) | RCE1PDE7ATEAD4 | |
| SCHEMBL719453 | 0.74 | RCE1 (0.60) | RCE1PDE7AMERTKTP53KDM4E | |
| SCHEMBL3110114 | 0.74 | RCE1 (0.45) | RCE1PDE7APOLBMAPTPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436043-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-07 | — | — | US | disclosed |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-25 | — | — | US | disclosed |
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-01 | — | — | US | disclosed |
| EP-2251326-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | RCE1 2661/4885PDE7A 2449/4885MERTK 3340/4885 |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | RCE1 2661/4885PDE7A 2449/4885MERTK 3340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.